LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Low-Cost, Portable Device Uses microRNA Technology to Diagnose Heart Attacks in Minutes

By LabMedica International staff writers
Posted on 07 Oct 2021
Image: Professor Zorlutuna in the lab (Photo courtesy of University of Notre Dame)
Image: Professor Zorlutuna in the lab (Photo courtesy of University of Notre Dame)

Researchers have developed a new sensor that could diagnose a heart attack in less than 30 minutes, according to a new study.

The low-cost, portable device developed by researchers from the University of Notre Dame’s College of Engineering (Notre Dame, IN, USA) and the University of Florida’s College of Medicine (Gainesville, FL, USA) could prove to be a boon for health care professionals as it takes them hours to diagnose a heart attack. Initial results from an echocardiogram can quickly show indications of heart disease, but to confirm a patient is having a heart attack, a blood sample and analysis is required. Those results can take up to eight hours.

By targeting three distinct types of microRNA or miRNA, the newly developed sensor can distinguish between an acute heart attack and a reperfusion - the restoration of blood flow, or reperfusion injury, and requires less blood than traditional diagnostic methods to do so. The ability to differentiate between someone with inadequate blood supply to an organ and someone with a reperfusion injury is an unmet, clinical need that this sensor addresses.

“The current methods used to diagnose a heart attack are not only time intensive, but they also have to be applied within a certain window of time to get accurate results,” said Pinar Zorlutuna, Sheehan Family Collegiate Professor of Engineering at Notre Dame. “Because our sensor targets a combination of miRNA, it can quickly diagnose more than just heart attacks without the timeline limitation.”

“The technology developed for this sensor showcases the advantage of using miRNA compared to protein-based biomarkers, the traditional diagnostic target,” said Hsueh-Chia Chang, Bayer Professor of Chemical and Biomolecular Engineering at Notre Dame. “Additionally, the portability and cost efficiency of this device demonstrates the potential for it to improve how heart attacks and related issues are diagnosed in clinical settings and in developing countries.”

Related Links:
University of Notre Dame 
University of Florida 

 

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Rapid Molecular Testing Device
FlashDetect Flash10

Channels

Molecular Diagnostics

view channel
Image: LiDia-SEQ aims to deliver near-patient NGS testing capabilities to hospitals, labs and clinics (Photo courtesy of DNAe)

World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device

Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
GLOBE SCIENTIFIC, LLC